Gelesis HoldingsInc.
Gelesis HoldingsInc. logo

Gelesis HoldingsInc. (GLS)


Market is closed
– opens on 8 PM, 31 Jan 2023
  • $







Key Stats

Day's Range
52-Week Range
1 month return42.02%
3 month return19.1%
1 year return94.09%
5 year return94.95%

Insights on Gelesis HoldingsInc.

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 7.51B → 6.65K (in $), with an average decrease of 62.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -12.59K → -14.22K (in $), with an average decrease of 13.0% per quarter

  • Vs Sun Pharmaceuticals Industries Ltd

    In the last 1 year, Sun Pharmaceuticals Industries Ltd has given 26.0% return, outperforming this stock by 58.8%

  • Vs Vertex Pharmaceuticals, Inc.

    In the last 1 year, Vertex Pharmaceuticals, Inc. has given 32.3% return, outperforming this stock by 125.2%

Analyst Recommendation

based on 8 analysts ratings


Based on 8 Wall street analysts offering stock ratings for Gelesis HoldingsInc.(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 49.25%






Market Capitalization27.0M
Book Value- $0.05
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)-10.86
Wall Street Target Price0.45


Trailing PE0.0
Forward PE0.0
Price/Book (mrq)5.23
Enterprise Value52.6M
Enterprise Value/Revenue4.71
Enterprise Value/Ebitda-0.6


50 Day MA0.35
200 Day MA1.78

Institutional Holdings

Allianz Asset Management AG


Vanguard Group Inc


Vitruvian Partners


Neuberger Berman Group LLC


BlackRock Inc


Cormorant Asset Management, LLC


Company Information

Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its non-systemic superabsorbent hydrogels are the first and only made entirely from naturally derived building blocks, and they are inspired by the composition (i.e., water & cellulose) and mechanical properties (e.g., elasticity or firmness) of raw vegetables. They are conveniently administered in capsules to create a much larger volume of small, non-aggregating hydrogel pieces that become an integrated part of the meals, and act locally in the digestive system. Its portfolio includes Plenity®, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
OrganizationGelesis HoldingsInc.
CEOMr. Yishai Zohar

Discover more

Frequently Asked Questions

What is Gelesis HoldingsInc. share price today?

Can Indians buy Gelesis HoldingsInc. shares?

How can I buy Gelesis HoldingsInc. shares from India?

Can Fractional shares of Gelesis HoldingsInc. be purchased?

What are the documents required to start investing in Gelesis HoldingsInc. stocks?

What are today’s High and Low prices of Gelesis HoldingsInc.?

What are today’s traded volumes of Gelesis HoldingsInc.?

What is today’s market capitalisation of Gelesis HoldingsInc.?

What is the 52 Week High and Low Range of Gelesis HoldingsInc.?

How much percentage Gelesis HoldingsInc. is down from its 52 Week High?

How much percentage Gelesis HoldingsInc. is up from its 52 Week low?

What are the historical returns of Gelesis HoldingsInc.?

Who is the Chief Executive Officer (CEO) of Gelesis HoldingsInc.?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*